相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
CLINICAL CANCER RESEARCH (2017)
Quantitative and pathologist-read comparison of the heterogeneity of programmed death-ligand 1 (PD-L1) expression in non-small cell lung cancer
Jamaal A. Rehman et al.
MODERN PATHOLOGY (2017)
Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC)
Qinxiang Guo et al.
THORACIC CANCER (2017)
Analysis of Fifty Hotspot Mutations of Lung Squamous Cell Carcinoma in Never-smokers
Ha Youn Lee et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2017)
Programmed Cell Death Ligand (PD-L1) Expression in Stage II and III Lung Adenocarcinomas and Nodal Metastases
Hironori Uruga et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
Matthew D. Hellmann et al.
LANCET ONCOLOGY (2017)
Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy
Thomas J. Gniadek et al.
MODERN PATHOLOGY (2017)
Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy
Teresa Davoli et al.
SCIENCE (2017)
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
Patricia Gaule et al.
JAMA ONCOLOGY (2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer
David L. Rimm et al.
JAMA ONCOLOGY (2017)
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer
Marianne J. Ratcliffe et al.
CLINICAL CANCER RESEARCH (2017)
Assessing PDL-1 and PD-1 in NoneSmall Cell Lung Cancer: A Novel Immunoscore Approach
Erna-Elise Paulsen et al.
CLINICAL LUNG CANCER (2017)
Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer
T. Donnem et al.
ANNALS OF ONCOLOGY (2016)
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies
M. Ilie et al.
ANNALS OF ONCOLOGY (2016)
Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group
Manfred Dietel et al.
THORAX (2016)
Non-Small Cell Lung Cancer, PD-L1, and the Pathologist
Keith M. Kerr et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Programmed Death Ligand-1 Immunohistochemistry Friend or Foe?
Keith M. Kerr et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
PD-L1 and Lung Cancer The Era of Precision-ish Medicine?
Alain C. Borczuk et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Programmed Death Ligand-1 Immunohistochemistry-A New Challenge for Pathologists A Perspective From Members of the Pulmonary Pathology Society
Lynette M. Sholl et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
PD-1/PD-L1, Only a Piece of the Puzzle
Ross A. Miller et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration
Chan-Young Ock et al.
CLINICAL CANCER RESEARCH (2016)
Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients
Edwin R. Parra et al.
CLINICAL CANCER RESEARCH (2016)
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
Justin F. Gainor et al.
CLINICAL CANCER RESEARCH (2016)
Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis
Omar Abdel-Rahman
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N
Jacquelyn Smith et al.
DIAGNOSTIC PATHOLOGY (2016)
Predictive relevance of PD-L1 expression combined with CD8+TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy
Takaaki Tokito et al.
EUROPEAN JOURNAL OF CANCER (2016)
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma
Ching-Yao Yang et al.
EUROPEAN JOURNAL OF CANCER (2016)
PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation
Ian A. Cree et al.
HISTOPATHOLOGY (2016)
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer
Elisabeth Brambilla et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Moving Programmed Death-1 Inhibitors to the Front Lines in Non-Small-Cell Lung Cancer
Justin F. Gainor
JOURNAL OF CLINICAL ONCOLOGY (2016)
Identification of Individual Cancer-Specific Somatic Mutations for Neoantigen-Based Immunotherapy of Lung Cancer
Takahiro Karasaki et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with Anti-PD-1/PD-L1 Antibodies
Takehito Shukuya et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Clinicopathologic Features of Advanced Squamous NSCLC
Mark A. Socinski et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
A Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana's Platform
Tzahi Neuman et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment
Tiffany G. Huynh et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer
Roy M. Bremnes et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Prognostic Significance of PD-L1 in Patients with Non-Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases
Jong-Mu Sun et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status
Yoon Jin Cha et al.
LUNG CANCER (2016)
Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)
Masaki Shimoji et al.
LUNG CANCER (2016)
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
Andreas H. Scheel et al.
MODERN PATHOLOGY (2016)
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Joshua D. Campbell et al.
NATURE GENETICS (2016)
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey et al.
SCIENCE (2016)
Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer
Dong-Qiang Zeng et al.
ONCOTARGET (2016)
Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N2) non-small cell lung cancer
Wen Feng et al.
ONCOTARGET (2016)
Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers
Marta Uso et al.
ONCOTARGET (2016)
Genetic alteration profiling of patients with resected squamous cell lung carcinomas
Dan Tao et al.
ONCOTARGET (2016)
PD-L1 Testing in Cancer Challenges in Companion Diagnostic Development
Aaron R. Hansen et al.
JAMA ONCOLOGY (2016)
PD-L1 Expression as a Predictive Biomarker Is Absence of Proof the Same as Proof of Absence?
Feriyl Bhaijee et al.
JAMA ONCOLOGY (2016)
Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer A Review
Adrian G. Sacher et al.
JAMA ONCOLOGY (2016)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer
Joseph McLaughlin et al.
JAMA ONCOLOGY (2016)
Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes
Patrick H. Lizotte et al.
JCI INSIGHT (2016)
Biomarker Testing in Non-Small Cell Lung Cancer A Clinician's Perspective
Eric Bernicker
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2015)
Classifying Cancers Based on T-cell Infiltration and PD-L1
Michele W. L. Teng et al.
CANCER RESEARCH (2015)
Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
Michael S. Rooney et al.
CELL (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Stromal CD8+ T-cell Density-A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer
Tom Donnem et al.
CLINICAL CANCER RESEARCH (2015)
Objective Measurement and Clinical Significance of TILs in Non-Small Cell Lung Cancer
Kurt A. Schalper et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor
Kyuichi Kadota et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer In what state is this art?
Keith M. Kerr et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
Antonio Calles et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers
Moon-Young Kim et al.
LUNG CANCER (2015)
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Wendy A. Cooper et al.
LUNG CANCER (2015)
Clinicopathologic analysis of programmed cell death-1 and programmed cell death-ligand 1 and 2 expressions in pulmonary adenocarcinoma: comparison with histology and driver oncogenic alteration status
Jaemoon Koh et al.
MODERN PATHOLOGY (2015)
Objective Measurement and Clinical Significance of TILs in Non-Small Cell Lung Cancer
Kurt A. Schalper et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
A 50-gene signature is a novel scoring system for tumor-infiltrating immune cells with strong correlation with clinical outcome of stage I/II non-small cell lung cancer
S. Hernandez-Prieto et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2015)
PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups
Lars Henning Schmidt et al.
PLOS ONE (2015)
Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression
Chunxiao Xu et al.
CANCER CELL (2014)
Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti et al.
LABORATORY INVESTIGATION (2014)
Comprehensive genomic characterization of squamous cell lung cancers
Peter S. Hammerman et al.
NATURE (2012)
The Use of P63 Immunohistochemistry for the Identification of Squamous Cell Carcinoma of the Lung
Esther Conde et al.
PLOS ONE (2010)
Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms
Enrico Ruffini et al.
ANNALS OF THORACIC SURGERY (2009)
Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification
B. Angulo et al.
JOURNAL OF PATHOLOGY (2008)
分享论文
